Home | Member Login | Join/Renew | Jobs | Contact
June 3, 2019, MedPage Today
CHICAGO -- Adding ribociclib (Kisqali) to endocrine therapy significantly prolonged survival in women with advanced HR-positive/HER-negative breast cancer, with a 29% lower risk of death, a researcher reported here.
Read more.
563 Carter Court, Suite B, Kimberly, WI 54136920-560-5620 / 800-545-0636920-882-3655 (fax)Email: APAOG@badgerbay.co
Quick Links
About APAOGContact UsJoin as a Member